Program
KH001
A development code. Also written as “KH-001 besylate” and “KH-001 ODT”.
Its studies are mostly in Dentin Sensitivity · Premature Ejaculation, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HysensBio | 30 open or running | phase 2since Mar 9, 2021 | Mar 9, 2021 | none ahead |
| Kadence Bio | 21 open or running | phase 2since Dec 10, 2025 | Dec 10, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2021First study: phase 2 study in Dentin SensitivityNew to HysensBioHysensBio · NCT04804514 · 40 enrolled · Korea, Republic of
- Feb 9, 2024Phase 2 study in Dentin SensitivityHysensBio · NCT06264453 · 171 enrolled · Korea, Republic of
- Jun 13, 2024Phase 2 study in Dentin SensitivityHysensBio · NCT06464939 · 120 enrolled · United States
- Dec 10, 2025Kadence Bio's first study: phase 2 study in Premature EjaculationNew to Kadence BioKadence Bio · NCT07434271 · 40 planned · Australia
- Sep 25, 2026Phase 1 study in Premature EjaculationKadence Bio · NCT07868237 · 82 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07868237Premature Ejaculation · United Kingdom | 1 | Completed | Kadence Bio | Aug 28, 2025 | 82 |
| NCT07434271Premature Ejaculation · Australia | 2 | Recruiting | Kadence Bio | Oct 31, 2026 | 40 |
| NCT06464939Dentin Sensitivity · United States | 2 | Completed | HysensBio | Dec 22, 2025 | 120 |
| NCT06264453Dentin Sensitivity · Korea, Republic of | 2 | Completed | HysensBio | Sep 25, 2024 | 171 |
| NCT04804514Dentin Sensitivity · Korea, Republic of | 2 | Completed | HysensBio | Mar 3, 2023 | 40 |
How it is read
Names in the registry
- “KH001”, 3 entries
- “KH-001 besylate”, 1 entry
- “KH-001 ODT”, 1 entry
Codes read as this program: KH001.
Conditions, from the studies’ own filings
- Dentin Sensitivity, 3 studies
- Premature Ejaculation, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.